Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 7/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5747674 | 1.00 | P2RX7 (0.48) | P2RX7ADORA1MC4RGRM5LMNA | |
| SCHEMBL5745574 | 0.90 | P2RX7 (0.48) | P2RX7ADORA1MC4RLMNATACR1 | |
| SCHEMBL5747016 | 0.90 | P2RX7 (0.48) | P2RX7ADORA1MC4RLMNATACR1 | |
| SCHEMBL5747701 | 0.90 | P2RX7 (0.48) | P2RX7ADORA1MC4RLMNAGLA | |
| SCHEMBL5747703 | 0.90 | P2RX7 (0.48) | P2RX7ADORA1MC4RLMNAGLA | |
| SCHEMBL5746808 | 0.89 | LMNA (0.49) | P2RX7ADORA1LMNATSHRMEN1 | |
| SCHEMBL5746802 | 0.89 | LMNA (0.49) | P2RX7ADORA1LMNATSHRMEN1 | |
| SCHEMBL5743443 | 0.87 | MAPT (0.50) | P2RX7ADORA1LMNATSHRMEN1 | |
| SCHEMBL5743445 | 0.87 | MAPT (0.50) | P2RX7ADORA1LMNATSHRMEN1 | |
| SCHEMBL5744094 | 0.86 | ADORA1 (0.52) | P2RX7ADORA1MC4RGRM5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487449-A4 | TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS | KING PHARMACEUTICALS RES & DEV (US) | 2006-08-23 | — | — | EP | claimed |
| US-7094895-B2 | Tyrosyl derivatives and their use as P2X7 receptor modulators | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2006-08-22 | — | — | US | claimed |
| EP-1487449-A1 | TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS | King Pharmaceuticals Research and Development Inc. (US) | 2004-12-22 | — | — | EP | claimed |
| US-20030181452-A1 | Tyrosyl derivatives and their use as P2X7 receptor modulators | CREDIT SUISSE AG | 2003-09-25 | — | — | US | claimed |
| WO-2003059353-A1 | TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| US-7094895-B2 | Tyrosyl derivatives and their use as P2X7 receptor modulators | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| US-20030181452-A1 | Tyrosyl derivatives and their use as P2X7 receptor modulators | CREDIT SUISSE AG | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181452-A1 | Tyrosyl derivatives and their use as P2X7 receptor modulators | P2RX7, P2RX3, P2RX5 | P2RX7 1/4885ADORA1 47/4885MC4R 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.